Filter by ContentType
Navigating the EU joint clinical assessment process: key considerations for manufacturers of ATMPs and oncology medicines
Clare L Hague
18 June 2024
Commentary
Will it be possible to find predictive genetic markers of immune checkpoint inhibitor toxicity that are not also predictive of survival?
Claire Palles, Ik Shin Chin
17 January 2024
Commentary
2024 and beyond: addressing ongoing safety and toxicity challenges for the future of the I-O field
Rakesh Dixit
25 October 2023
Commentary
Alloplex Biotherapeutic’s SUPLEXA cells represent a new type of autologous adoptive cellular therapy for cancer
Frank Borriello, James A Lederer
25 April 2023
Commentary
Overcoming challenges to CAR-T cell therapies in India
A Uppal, R Chakrabarti, N Chirmule et al
08 March 2023
Commentary
Translational mouse models for immuno-oncology: from syngeneic to humanized models
Stephanie C Casey
28 September 2022
Commentary
Why we need a revolution for personalized cell therapies
S Steiner, B Gilgen, E Pernot et al
06 July 2022
Commentary
Addressing the challenges of CRS in bispecific monoclonal antibody cancer therapy
Anjali Vaze, Peter Kuebler
16 June 2022
Commentary
Patient-centered care in immuno-oncology: current progress & opportunities when considering safety & tolerability
Céline Adessi, Dominik Rüttinger
18 May 2022
Commentary
A winning combination in the war against deadly cancers: exploring new opportunities for combining antibody–drug conjugates and cancer immunotherapies
Rakesh Dixit
20 April 2022
Commentary
Cancer immunotherapy & clinical trial design: issues & practice
Janet E Dancey, MD, FRCPC
30 March 2022
Commentary
Quantifying the tumor microenvironment: what is the next step to advance cancer immunotherapy?
Ning Wang
27 March 2022
Commentary
Raiders of the lost art: finding immuno-oncology treasure
Kishore K Gangangari, Anthony Murphy, Reni Benjamin
21 March 2022
Commentary
Immuno-oncology therapies: a looming mid-life crisis?
Hansoo Kim, Danny Liew, Stephen Goodall
15 March 2022
Commentary
The cutting edge: leveraging pre-surgical immunotherapy trials to understand therapeutic mechanisms
Bailey G Fitzgerald, Matthew D Galsky, Thomas U Marron
15 March 2022
Commentary
BCMA targeting CAR T cells using a novel D-domain binder for multiple myeloma: clinical development update
A Rotte, C Heery, B Gliner et al
24 January 2022
Commentary
Yes, IMMUcan! Unraveling the human tumor microenvironment
Henoch Hong, Robin Liechti, Marie Morfouace
14 October 2021
Commentary
Cancer in 4D: the importance of spatial and temporal heterogeneity through breast cancer molecular cartography
Constanza Martinez
11 October 2021
Commentary
Towards the rational design of a next-generation dendritic cell vaccine for cancer immunotherapy
Marcelo Bravo, Timothy J Davies, Paul J Fairchild
08 June 2021
Commentary
Future-proofing cell therapy manufacturing capability: lessons from the NCI
Anthony Welch, Marc Ernstoff, Jason Yovandich
20 April 2021
Commentary
Antigen-presenting dendritic cells as targets for cancer immunotherapy
David H. Munn, Rafal Pacholczyk, Madhav D. Sharma
29 January 2021
Commentary